首页> 外国专利> SUBSTITUTED ARYLPYRAZINES, PHARMACEUTICAL COMPOSITION BASED THEREOF, METHOD FOR MODULATION OF CRF RECEPTORS FUNCTION, METHOD FOR TREATMENT OF CNS-RELATED DISORDERS AND DISEASES, METHOD FOR LOCALIZATION OF CRF RECEPTORS IN TISSUE SPECIMENS, METHOD FOR INHIBITION OF CFR RECEPTOR BINDING WITH CRF1 RECEPTOR, METHOD FOR CHANGING ACTIVITY OF TRANSDUCTION CFR1 RECEPTOR SIGNAL, METHOD FOR MODULATION OF FUNCTION G PROTEIN-COUPLED RECEPTOR

SUBSTITUTED ARYLPYRAZINES, PHARMACEUTICAL COMPOSITION BASED THEREOF, METHOD FOR MODULATION OF CRF RECEPTORS FUNCTION, METHOD FOR TREATMENT OF CNS-RELATED DISORDERS AND DISEASES, METHOD FOR LOCALIZATION OF CRF RECEPTORS IN TISSUE SPECIMENS, METHOD FOR INHIBITION OF CFR RECEPTOR BINDING WITH CRF1 RECEPTOR, METHOD FOR CHANGING ACTIVITY OF TRANSDUCTION CFR1 RECEPTOR SIGNAL, METHOD FOR MODULATION OF FUNCTION G PROTEIN-COUPLED RECEPTOR

机译:取代的芳基吡嗪类药物,基于其的药物组合物,CRF受体功能的调节方法,CNS相关疾病和疾病的治疗方法,组织标本中CRF受体的定位方法,受体的抑制方法转化CFR1受体信号的改变活性,功能G蛋白偶联受体的调制方法

摘要

Arylpyrazine compounds are provided, including arylpyrazines that can bind with high affiity and high selectivity to CRF1 receptors, including human CRF1 receptors. The invention thus includes methods for treatment of disorders and diseases associated with CRF1 receptors, including CNS-related disorders and diseases, particularly affective disorders and diseases, and acute and chronic neurological disorders and diseases.
机译:提供了芳基吡嗪化合物,包括可以以高亲和力和高选择性结合至包括人CRF1受体的CRF1受体的芳基吡嗪。因此,本发明包括用于治疗与CRF1受体有关的病症和疾病的方法,包括与CNS相关的病症和疾病,特别是情感性病症和疾病,以及急慢性神经病症和疾病。

著录项

  • 公开/公告号UA75586C2

    专利类型

  • 公开/公告日2003-08-15

    原文格式PDF

  • 申请/专利权人 NEUROGEN CORPORATION;

    申请/专利号UA20020076329

  • 发明设计人

    申请日2001-02-16

  • 分类号A61K31/496;A61P25;C07D;C07D241/18;C07D241/20;C07D401/04;C07D401/12;C07D403/04;C07D405/12;

  • 国家 UA

  • 入库时间 2022-08-22 00:01:08

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号